Active Ingredient History

NOW
  • Now
Odalasvir is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by Achillion Pharmaceuticals.   Wikipedia

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1c3nc4cc(ccc4[nH]3)c5cc6CCc7ccc(CCc5cc6)cc7c8ccc9[nH]c(nc9c8)[C@@H]%10C[C@@H]%11CCCC[C@@H]%11N%10C(=O)[C@@H](NC(=O)OC)C(C)C
  • InChIKey: LSYBRGMTRKJATA-IVEWBXRVSA-N
  • Mol. Mass: 1001.29
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
ach-0143102 | ach-3102 | odalasvir

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue